What's new

Life Science Mentors – Mentoring Service for Finnish Life Science Actors

Finnish industry organisations in the Life Science field have collaboratively created an internet based mentoring service for start-up companies, fledgling entrepreneurs and researchers interested in commercialising their inventions. The purpose of the service is to share the knowledge of experienced people with beginners and support their business development. The service is offered free of charge.

Faron Pharmaceuticals Admission to AIM and first day of dealings £10 million fundraise to progress Phase III clinical trial

Faron Pharmaceuticals Oy ("Faron”), the clinical stage biopharmaceutical company, is pleased to announce the commencement of dealings in its Ordinary Shares on the AIM market of the London Stock Exchange with effect from 8.00 a.m. today under the ticker FARN and the ISIN number FI4000153309. This follows a successful placing and subscription for 3,846,154 new Ordinary Shares, raising £10.0 million at a price of 260p per ordinary share (the “Fundraising”).

Faron Enters Agreement with Selexis SA to Progress Development of Novel Cancer Immunotherapy Clevegen

Faron Pharmaceuticals Oy (”Faron”), the clinical stage biopharmaceutical company, announced today it has entered into an agreement with Swiss-based Selexis SA. Under the agreement, Faron will have access to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the production of high-expressing and stable clonal cell lines for use in the development and production of Clevegen, its novel cancer immunotherapy antibody.

  1. Fimmic closes investment round to digitalize cancer diagnostics
  2. Faron Pharmaceuticals Oy Intention to Float on AIM
  3. Innomedica to open new office in Switzerland
  4. FIT Biotech’s Initial Public Offering Completed Successfully
  5. BioFinland prize to Biovian Oy
  6. Forendo Pharma announces the US licensing of fispemifene to Apricus Biosciences targeting urological conditions in men
  7. Oncos Therapeutics Demonstrates Systemic, Tumor-specific Immune Response by Local Administration of its Lead Product ONCOS-102
  8. Promising new treatment for life threatening acute respiratory distress syndrome (ARDS)
  9. A Special Year for the Biotech Sector
  10. KU Leuven and FIT Biotech enter into a worldwide license and collaboration agreement for the development of novel immunotherapeutics
  11. Neste Jacobs and Roal Sign a Contract to Expand Enzyme Production Plant
  12. BioFinland 2013 prize to Glykos Finland Ltd
  13. Culminatum Innovation and Diaceutics Collaborate to Provide Expert Training to Leading Finnish Researchers on Commercializing Biomarkers for Personalized Medicine
  14. Innomedica and CMC Biologics into strategic agreement for Japan market
  15. The Future Generation of Bioscientists - Lost or Found?
  16. Culminatum works to develop an attractive innovation environment for biotechnology in the BSR
  17. New Horizons For the Bioindustry
  18. Faron reports positive headline data from FPCLI001 clinical study with FP- 1201 in acute lung injuries
  19. An Insider’s View: Report on the Finnish Life Sciences Industry
  20. Faron and Maruishi Sign Traumakine-program License Agreement
  21. Rentschler to manufacture Faron product Traumakine®
  22. Change of management in Novamass Ltd
  23. Fulfilling the Promises
  24. Innomedica Expands in UK – Dr Jim Phillips Joins the Team
  25. Finland is a Forerunner in Biomass Refining
  26. Biobanks—Opportunities Becoming Reality
  27. The Perceived Value-added of Venture Capital Investors: Evidence from Finnish biotechnology industry
  28. Coaching small biotech companies into success: The value-adding function of VC
  29. Promoting innovation by tax incentives—A review of strategies and their importance to biotech growth
  30. European Biotech industry figures show signs of chronic under-funding
  31. ETLA 2004 Survey on the Finnish Biotechnology Industry--Background and Descriptive Statistics
  32. State of the Biotechnology Industry
  33. Intellectual Capital and Anticipated Future Sales in Small and Medium-sized Biotechnology Companies
  34. Ownership and Financial Structure of Biotechnology SMEs: Evidence from Finland
  35. Findings of the ETLA Survey on Finnish Biotechnology Firms
  • You are here:  
  • Home
  • What's new